According to Zacks, “Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company’s product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California. “
Separately, HC Wainwright started coverage on shares of Menlo Therapeutics in a report on Friday, October 18th. They issued a “buy” rating and a $11.00 price objective for the company.
Menlo Therapeutics (NASDAQ:MNLO) last issued its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.07. On average, analysts predict that Menlo Therapeutics will post -3.08 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNLO. BlackRock Inc. increased its holdings in Menlo Therapeutics by 44.7% in the second quarter. BlackRock Inc. now owns 912,720 shares of the company’s stock valued at $5,466,000 after buying an additional 281,974 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Menlo Therapeutics by 131.6% in the second quarter. Renaissance Technologies LLC now owns 110,000 shares of the company’s stock valued at $659,000 after buying an additional 62,500 shares in the last quarter. Orbimed Advisors LLC increased its holdings in Menlo Therapeutics by 6.3% in the second quarter. Orbimed Advisors LLC now owns 673,700 shares of the company’s stock valued at $4,035,000 after buying an additional 39,780 shares in the last quarter. State Street Corp increased its holdings in Menlo Therapeutics by 15.3% in the third quarter. State Street Corp now owns 240,520 shares of the company’s stock valued at $1,078,000 after buying an additional 31,998 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in Menlo Therapeutics by 73.7% in the second quarter. Parametric Portfolio Associates LLC now owns 66,972 shares of the company’s stock valued at $401,000 after buying an additional 28,418 shares in the last quarter. 58.67% of the stock is owned by institutional investors.
About Menlo Therapeutics
Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.
Recommended Story: Limitations to arbitrage trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.